Our story


Our story

Precision began when our co-founders, neurosurgeon and engineer Ben Rapoport and business builder Michael Mager, joined forces to realize Ben’s lifelong dream of bringing brain–computer interfaces (BCIs) to the medical field. We set out to develop something that had never been built before: a high-bandwidth digital connection to the brain that did not rely on penetrating electrodes, which damage brain tissue. Our vision of a safe, minimally invasive brain–computer interface informed not just the product but also the kind of company we wanted to build: one that would push the boundaries of new technology while remaining laser-focused on human health.

We began work in 2021 with a team of four people, three of whom had spent time together at Neuralink. Since then, we’ve developed our core product, a high resolution cortical surface array called the Layer 7 Cortical Interface, and begun manufacturing it in a facility that we own and control. We’ve started testing our device in patients, and are currently expanding our clinical presence. We anticipate having our first commercial product on the market in 2025.

The first application for our system will be a goal that BCI researchers have long sought: restoring functions such as speech and movement to millions of severely paralyzed people. We are investigating other areas where our system can make a clinical impact in the near future; stroke rehabilitation and refractory depression are at the top of the list. A high-bandwidth brain–computer interface is a foundational technology. It forges a direct connection between human and artificial intelligence. We believe that the implications—for medicine, science, and humanity—are profound, and we feel lucky to be a part of this new era.


"We believe that it’s possible to interface with the brain without damaging the brain."

Dr. Ben RapoportMD, PhD/Chief Science Officer

Company Milestones

    Precision launches, raises first capital
    Patent the minimally invasive microslit technique
     Develop and patent the first version of the Layer 7 Cortical Interface
    Series B capital raise
    Double the channel count of microelectrode array
    Submit 17 new patent applications
    Launch clinical partnership with West Virginia University; first human implantation
    Acquire and integrate Precision BioMEMS, a microfabrication facility for medical devices
    FDA Breakthrough Designation
    Launch clinical partnerships with Penn Medicine and Mount Sinai


  • Benjamin RapoportChief Science Officer, Co-Founder
    Benjamin RapoportChief Science Officer, Co-Founder

    In addition to overseeing Precision's scientific and clinical work, Rapoport is a practicing neurosurgeon at New York City’s Mount Sinai Hospital, where he specializes in minimally invasive neurosurgery. He has been developing brain–computer interface technology for nearly two decades. He has an MD from Harvard Medical School, a PhD in electrical engineering and computer science from MIT, and was on the eight-member co-founding team of Neuralink.

  • Michael MagerChief Executive Officer, Co-Founder
    Michael MagerChief Executive Officer, Co-Founder

    Mager has built, invested in, and managed companies across diverse geographies and industries, with a focus on technology and technology-enabled businesses. He received his undergraduate degree from Harvard College and earned an MPhil degree in economic history from the University of Cambridge.

  • Craig MermelPresident and Chief Product Officer
    Craig MermelPresident and Chief Product Officer

    Mermel is a pathologist trained in the study of cancer genomics. He was previously at Google, where he led a team exploring the use of artificial intelligence to diagnose and treat cancer. Before that, he spent four years at Apple, helping to develop health and fitness features for the Apple Watch. With Ben Rapoport, he co-founded the digital health company Simbionics, aquired by Apple in 2014. He holds an MD and PhD in genetics from Harvard University.

  • Mike KaswanChief Financial Officer
    Mike KaswanChief Financial Officer

    Kaswan has over 30 years of experience as a CFO, CEO, venture capital investor and entrepreneur in healthcare. He was previously CFO of Orchestra BioMed Holdings, which he helped take public in 2022. He has a BS in commerce from the University of Virginia and an MBA from Harvard Business School.

  • Brian Otis Chief Technology Officer
    Brian Otis Chief Technology Officer

    An expert in chip design for low-power electronics, Otis was a co-founder of Verily Life Sciences, Alphabet Inc.’s healthcare-focused research organization, where he served as Chief Technical Officer and Fellow from 2015 through 2022. Previously, he was a tenured professor at the University of Washington’s Department of Electrical and Computer Engineering, where he pioneered techniques for creating highly miniaturized wearable, implantable, and on-eye wireless sensors. He received his MS and PhD in electrical engineering from the University of California, Berkeley.

Team Spotlight

  • Ajit PillaiVP of Program Management
  • Helen MelvilleSenior Manager, People Operations
  • Mark HettickHead of Microfabrication
  • Nicholas BernsteinVP, Business Development and Corporate Strategy
  • Adam Poole Manager, Mechanical Engineering
  • Fraser TanSenior R&D Program Manager
  • Elton HoSenior Neural Interface Engineer
  • Stephanie RiderOperations Manager, Arrays